Matthew B. Neiditch
Rutgers University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Matthew B. Neiditch.
Antimicrobial Agents and Chemotherapy | 2012
Karthik Sambanthamoorthy; Rudolph E. Sloup; Vijay Parashar; Joshua M. Smith; Eric E. Kim; M. F. Semmelhack; Matthew B. Neiditch; Christopher M. Waters
ABSTRACT Bacterial biofilm formation is responsible for numerous chronic infections, causing a severe health burden. Many of these infections cannot be resolved, as bacteria in biofilms are resistant to the hosts immune defenses and antibiotic therapy. New strategies to treat biofilm-based infections are critically needed. Cyclic di-GMP (c-di-GMP) is a widely conserved second-messenger signal essential for biofilm formation. As this signaling system is found only in bacteria, it is an attractive target for the development of new antibiofilm interventions. Here, we describe the results of a high-throughput screen to identify small-molecule inhibitors of diguanylate cyclase (DGC) enzymes that synthesize c-di-GMP. We report seven small molecules that antagonize these enzymes and inhibit biofilm formation by Vibrio cholerae. Moreover, two of these compounds significantly reduce the total concentration of c-di-GMP in V. cholerae, one of which also inhibits biofilm formation by Pseudomonas aeruginosa in a continuous-flow system. These molecules represent the first compounds described that are able to inhibit DGC activity to prevent biofilm formation.
Molecular Microbiology | 2013
Disha Srivastava; Meng Lun Hsieh; Atul Khataokar; Matthew B. Neiditch; Christopher M. Waters
Cyclic di‐GMP (c‐di‐GMP) controls the transition between sessility and motility in many bacterial species. This regulation is achieved by a variety of mechanisms including alteration of transcription initiation and inhibition of flagellar function. How c‐di‐GMP inhibits the motility of Vibrio cholerae has not been determined. FlrA, a homologue of the c‐di‐GMP binding Pseudomonas aeruginosa motility regulator FleQ, is the master regulator of the V. cholerae flagellar biosynthesis regulon. Here we show that binding of c‐di‐GMP to FlrA abrogates binding of FlrA to the promoter of the flrBC operon, deactivating expression of the flagellar biosynthesis regulon. FlrA does not regulate expression of extracellular Vibrio polysaccharide (VPS) synthesis genes. Mutation of the FlrA amino acids R135 and R176 to histidine abrogates binding of c‐di‐GMP to FlrA, rendering FlrA active in the presence of high levels of c‐di‐GMP. Surprisingly, c‐di‐GMP still inhibited the motility of V. cholerae only expressing the c‐di‐GMP blind FlrA(R176H) mutant. We determined that this flagellar transcription‐independent inhibition is due to activation of VPS production by c‐di‐GMP. Therefore, c‐di‐GMP prevents motility of V. cholerae by two distinct but functionally redundant mechanisms.
PLOS Biology | 2011
Vijay Parashar; Nicolas Mirouze; David Dubnau; Matthew B. Neiditch
Crystallographic, biochemical, and genetic studies reveal the mechanism of Rap protein phosphatase activity within the phosphorelay pathway leading to sporulation in Bacillus species.
Nature Chemical Biology | 2013
Regina Wilson; Pradeep Kumar; Vijay Parashar; Catherine Vilchèze; Romain Veyron-Churlet; Joel S. Freundlich; S. Whitney Barnes; John R. Walker; Michael J. Szymonifka; Emily Marchiano; Shubhada Shenai; Roberto Colangeli; William R. Jacobs; Matthew B. Neiditch; Laurent Kremer; David Alland
We report a new class of thiophene (TP) compounds that kill Mycobacterium tuberculosis (Mtb) by the novel mechanism of Pks13 inhibition. An F79S mutation near the catalytic Ser-55 site in Pks13 conferred TP-resistance in Mtb. Over-expression of wild-type pks13 resulted in TP-resistance and over-expression of the F79S pks13 mutant conferred high-level resistance. In vitro, TP inhibited fatty acyl-AMP loading onto Pks13. TP inhibited mycolic acid biosynthesis in wild-type Mtb, but to a much lesser extent in TP-resistant Mtb. TP treatment was bactericidal and equivalent to the first-line drug isoniazid, but it was less likely to permit emergent resistance. Combined isoniazid and TP treatment exhibited sterilizing activity. Computational-docking identified a possible TP-binding groove within the Pks13 ACP domain. This study confirms that Mtb Pks13 is required for mycolic acid biosynthesis, validates it as a druggable target and demonstrates the therapeutic potential of simultaneously inhibiting multiple targets in the same biosynthetic pathway.
Antimicrobial Agents and Chemotherapy | 2011
Karthik Sambanthamoorthy; Ankush A. Gokhale; Weiwei Lao; Vijay Parashar; Matthew B. Neiditch; M. F. Semmelhack; Ilsoon Lee; Christopher M. Waters
ABSTRACT Bacterial biofilm formation causes significant industrial economic loss and high morbidity and mortality in medical settings. Biofilms are defined as multicellular communities of bacteria encased in a matrix of protective extracellular polymers. Because biofilms have a high tolerance for treatment with antimicrobials, protect bacteria from immune defense, and resist clearance with standard sanitation protocols, it is critical to develop new approaches to prevent biofilm formation. Here, a novel benzimidazole molecule, named antibiofilm compound 1 (ABC-1), identified in a small-molecule screen, was found to prevent bacterial biofilm formation in multiple Gram-negative and Gram-positive bacterial pathogens, including Pseudomonas aeruginosa and Staphylococcus aureus, on a variety of different surface types. Importantly, ABC-1 itself does not inhibit the growth of bacteria, and it is effective at nanomolar concentrations. Also, coating a polystyrene surface with ABC-1 reduces biofilm formation. These data suggest ABC-1 is a new chemical scaffold for the development of antibiofilm compounds.
PLOS Biology | 2011
Melinda D. Baker; Matthew B. Neiditch
Structure-function studies reveal that Rap proteins have distinct, nonoverlapping surfaces that interact with different cellular targets, and that for antiactivator RapF, one surface mimics DNA to bind a response regulator DNA binding domain, thereby sterically preventing the activity of this transcription transactivator.
Retrovirology | 2011
Aprille Rapista; Jian Ding; Bernadette Benito; Yung Tai Lo; Matthew B. Neiditch; Wuyuan Lu; Theresa L. Chang
BackgroundConcurrent sexually transmitted infections (STIs) increase the likelihood of HIV transmission. The levels of defensins are frequently elevated in genital fluids from individuals with STIs. We have previously shown that human defensins 5 and 6 (HD5 and HD6) promote HIV entry and contribute to Neisseria gonorrhoeae-mediated enhancement of HIV infectivity in vitro. In this study, we dissect the molecular mechanism of the HIV enhancing effect of defensins.ResultsHD5 and HD6 primarily acted on the virion to promote HIV infection. Both HD5 and HD6 antagonized the anti-HIV activities of inhibitors of HIV entry (TAK 779) and fusion (T-20) when the inhibitors were present only during viral attachment; however, when these inhibitors were added back during viral infection they overrode the HIV enhancing effect of defensins. HD5 and HD6 enhanced HIV infectivity by promoting HIV attachment to target cells. Studies using fluorescent HIV containing Vpr-GFP indicated that these defensins enhanced HIV attachment by concentrating virus particles on the target cells. HD5 and HD6 blocked anti-HIV activities of soluble glycosaminoglycans including heparin, chondroitin sulfate, and dextran sulfate. However, heparin, at a high concentration, diminished the HIV enhancing effect of HD5, but not HD6. Additionally, the degree of the HIV enhancing effect of HD5, but not HD6, was increased in heparinase-treated cells. These results suggest that HD5 and haparin/heparan sulfate compete for binding to HIV.ConclusionsHD5 and HD6 increased HIV infectivity by concentrating virus on the target cells. These defensins may have a negative effect on the efficacy of microbicides, especially in the setting of STIs.
PLOS Biology | 2013
Vijay Parashar; Philip D. Jeffrey; Matthew B. Neiditch
Structure-function studies reveal hojavascript:popupCustomFlags(‘pbiology’,%2013052,%20‘Submission’)w a family of bacterial cell-cell signaling peptides function mechanistically to regulate their cytoplasmic target receptors.
Journal of Bacteriology | 2013
Vijay Parashar; Melissa A. Konkol; Daniel B. Kearns; Matthew B. Neiditch
Bacillus subtilis biofilm formation is tightly regulated by elaborate signaling pathways. In contrast to domesticated lab strains of B. subtilis which form smooth, essentially featureless colonies, undomesticated strains such as NCIB 3610 form architecturally complex biofilms. NCIB 3610 also contains an 80-kb plasmid absent from laboratory strains, and mutations in a plasmid-encoded homolog of a Rap protein, RapP, caused a hyperrugose biofilm phenotype. Here we explored the role of rapP phrP in biofilm formation. We found that RapP is a phosphatase that dephosphorylates the intermediate response regulator Spo0F. RapP appears to employ a catalytic glutamate to dephosphorylate the Spo0F aspartyl phosphate, and the implications of the RapP catalytic glutamate are discussed. In addition to regulating B. subtilis biofilm formation, we found that RapP regulates sporulation and genetic competence as a result of its ability to dephosphorylate Spo0F. Interestingly, while rap phr gene cassettes routinely form regulatory pairs; i.e., the mature phr gene product inhibits the activity of the rap gene product, the phrP gene product did not inhibit RapP activity in our assays. RapP activity was, however, inhibited by PhrH in vivo but not in vitro. Additional genetic analysis suggests that RapP is directly inhibited by peptide binding. We speculate that PhrH could be subject to posttranslational modification in vivo and directly inhibit RapP activity or, more likely, PhrH upregulates the expression of a peptide that, in turn, directly binds to RapP and inhibits its Spo0F phosphatase activity.
Proceedings of the National Academy of Sciences of the United States of America | 2015
Vijay Parashar; Chaitanya Aggarwal; Michael J. Federle; Matthew B. Neiditch
Significance Peptide pheromones regulate developmental processes, including virulence, in Gram-positive bacteria. Immature propeptide pheromones are synthesized, secreted, and undergo proteolytic maturation to serve as intercellular signals. The regulator gene of glucosyltransferase (Rgg) transcription factors are a large family of receptors that directly bind pheromones transported to the cytosol. Here we report X-ray crystal structures of a Streptococcus Rgg protein alone and complexed with cyclosporin A, which is a potent inhibitor of pheromone signaling. Based on these structures and extensive genetic and biochemical studies, we mapped the pheromone-binding site, discovered mechanistic aspects of Rgg regulation, and determined how cyclosporin A and its nonimmunosuppressive analog valspodar function to inhibit pheromone-mediated receptor activation. We conclude that similar compounds targeting bacterial pheromone receptors have potential for therapeutic applications. Peptide pheromone cell–cell signaling (quorum sensing) regulates the expression of diverse developmental phenotypes (including virulence) in Firmicutes, which includes common human pathogens, e.g., Streptococcus pyogenes and Streptococcus pneumoniae. Cytoplasmic transcription factors known as “Rgg proteins” are peptide pheromone receptors ubiquitous in Firmicutes. Here we present X-ray crystal structures of a Streptococcus Rgg protein alone and in complex with a tight-binding signaling antagonist, the cyclic undecapeptide cyclosporin A. To our knowledge, these represent the first Rgg protein X-ray crystal structures. Based on the results of extensive structure–function analysis, we reveal the peptide pheromone-binding site and the mechanism by which cyclosporin A inhibits activation of the peptide pheromone receptor. Guided by the Rgg–cyclosporin A complex structure, we predicted that the nonimmunosuppressive cyclosporin A analog valspodar would inhibit Rgg activation. Indeed, we found that, like cyclosporin A, valspodar inhibits peptide pheromone activation of conserved Rgg proteins in medically relevant Streptococcus species. Finally, the crystal structures presented here revealed that the Rgg protein DNA-binding domains are covalently linked across their dimerization interface by a disulfide bond formed by a highly conserved cysteine. The DNA-binding domain dimerization interface observed in our structures is essentially identical to the interfaces previously described for other members of the XRE DNA-binding domain family, but the presence of an intermolecular disulfide bond buried in this interface appears to be unique. We hypothesize that this disulfide bond may, under the right conditions, affect Rgg monomer–dimer equilibrium, stabilize Rgg conformation, or serve as a redox-sensitive switch.